Clinical trial NCT03110588: Phase I Trial of PACE for Metastatic Prostate Cancer
Official title: Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Metastatic Prostate Cancer
Keywords: metastatic prostate cancer
castration-resistant prostate cancer
PACE (Prednisone, Abiraterone, Cabazitaxel, and Enzalutamide)
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: Astellas Pharma Inc
name: Sanofi
First posted: 2017-04-12
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The first cohort will administer the following to three patients: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks. If there are no dose limiting toxicities, the cabazitaxel will be escalated to 20 mg/m2 in a second cohort. The other three drugs will remain at the same dose.
Primary purpose: TREATMENT

Brief summary: This trial is being conducted to determine the feasibility and recommended dose of the combination of four drugs (prednisone, abiraterone, cabazitaxel and enzalutamide (PACE) as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).

Detailed description: Multiple agents have been shown to improve survival in patients with mCRPC by up to five months. The combination of prednisone, abiraterone, cabazitaxel and enzalutamide may be anticipated to be feasible therapy with minimal or no adverse drug interactions. This is a phase I trial to study the feasibility of the proposed therapy.

Patients will undergo a combination of oral daily drug intake at varying doses over a period of three weeks. Monitoring including blood collection for laboratory testing will be done on Day 1 of each three-week cycle with additional monitoring during the first cycle. Imaging and correlative studies will be done every 12 weeks. Therapy will continue until disease progression or severe toxicities.

Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years
2. Histologically proven adenocarcinoma of the prostate with metastatic disease.
3. Progressive disease following androgen deprivation therapy; Prostate Specific Antigen (PSA) progression defined as baseline increase followed by any PSA increase greater than or equal to 1 week apart.
4. Most recent PSA ≥2 ng/ml
5. Testosterone \< 50 ng/dL
6. Anti-androgen withdrawal of first generation AR inhibitors (bicalutamide, nilutamide) is required for 6 weeks if previous duration of stability on them was ≥3 months.
7. ECOG performance status 0-1.
8. Adequate organ function as defined below:

   ANC 1,500/µl; Hemoglobin 10 g/dL; Platelet count 100,000/µL; Creatinine clearance ≥45 ml/min; Potassium \>3.5 mmol/L (or within institutional normal range) Bilirubin ≤ ULN (unless documented Gilbert's disease); SGOT (AST) 1.5 x ULN; SGPT (ALT) 1.5 x ULN
9. Subject agrees to use a double barrier method of contraception during the course of study therapy and for at least 3 months after completion of therapy. A double barrier method involves the use of a condom in combination one of the following: sponge, diaphragm, cervical ring with spermicidal gel or foam. Subjects who have had a vasectomy ≥6 months prior to trial therapy and those with female sexual partners who are 55 years old and post-menopausal for 2 years or sterile (by tubectomy, hysterectomy, bilateral oophorectomy) need to agree to use at least a condom.
10. Ability to sign a written informed consent form.
11. Subject is willing to stop herbal supplements.

Exclusion Criteria:

1. Prior docetaxel for castration-resistant disease (prior docetaxel for castration-sensitive disease is allowed but not required).
2. Prior enzalutamide, abiraterone, cabazitaxel.
3. History of severe hypersensitivity reaction (≥grade 3) to docetaxel.
4. History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs.
5. Concomitant vaccination with yellow fever vaccine.
6. Prior investigational androgen synthesis or androgen receptor antagonists.
7. Prior hypersensitivity reaction to capsule components of enzalutamide including labrasol, butylated hydroxyanisole and butylated hydroxytoluene
8. Other non-chemotherapeutic investigational agents within 14 days (prior chemotherapy needs a ≥4 week washout).
9. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments).
10. Prior isotope therapy with Strontium-89, Samarium or radium-223.
11. Patients with a history of central nervous system metastases (brain, meninges, spinal cord).
12. Imminent risk of pathologic fracture or cord compression.
13. History of seizures, underlying brain injury with loss of consciousness, transient ischemic attack within 12 months, cerebrovascular accident, and brain arteriovenous malformations.
14. Uncontrolled severe intercurrent illness or medical conditions including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, uncontrolled diabetes mellitus, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or concurrent medications that alter cardiac conduction.
15. Patients with a "currently active" second malignancy other than non- melanoma skin or superficial urothelial cancers are not eligible. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are now considered without evidence of disease for 3 years.

Primary outcomes:
measure: Maximum tolerated dose of PACE as first-line therapy
timeFrame: Baseline up to 2 years
Secondary outcomes:
measure: Prostate specific antigen (PSA)
timeFrame: Baseline up to 2 years
measure: Radiographic progression-free survival with PACE
timeFrame: Baseline up to 2 years
measure: Progression-free survival with PACE
timeFrame: Baseline up to 2 years
measure: Objective response rate of measurable disease
timeFrame: Baseline up to 2 years
measure: Pain response
timeFrame: Baseline up to 2 years
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Mansoor N Saleh, MD
role: PRINCIPAL_INVESTIGATOR
References: